The DOI matches its Crossref record; 304 of the 304 references it cites were found in a registry or an index.
Understanding and targeting resistance mechanisms in NSCLC
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–304 of 304
Tiedt, R., Degenkolbe, E., Furet, P., Appleton, B. A., Wagner, S., Schoepfer, J. G., Buck, E., Ruddy, D. A., Monahan, J. E., Jones, M. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4433 · Cited by 139
Nakano, H., Yamamoto, F., Neville, C., Evans, D., Mizuno, T., & Perucho, M. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.1.71 · Cited by 133
Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers
Litvak, A. M., Paik, P. K., Woo, K. M., Sima, C. S., Hellmann, M. D., Arcila, M. E., Ladanyi, M., Rudin, C. M., Kris, M. G., & Riely, G. J. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000344 · Cited by 133
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 133
Yoshida, T., Ishii, G., Goto, K., Neri, S., Hashimoto, H., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0846 · Cited by 133
Ou, S. I., Young, L., Schrock, A. B., Johnson, A., Klempner, S. J., Zhu, V. W., Miller, V. A., & Ali, S. M. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.119 · Cited by 133
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors
Kosaka, T., Tanizaki, J., Paranal, R. M., Endoh, H., Lydon, C., Capelletti, M., Repellin, C. E., Choi, J., Ogino, A., Calles, A., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3404 · Cited by 131
Song, A., Kim, T. M., Kim, D., Kim, S., Keam, B., Lee, S., & Heo, D. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1350 · Cited by 131
Molecular Pathways: AXL, a Membrane Receptor Mediator of Resistance to Therapy
Scaltriti, M., Elkabets, M., & Baselga, J. M. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1458 · Cited by 130
Armstrong, F., Duplantier, M.-M., Trempat, P., Hiéblot, C., Lamant, L., Espinos, E., Racaud‐Sultan, C., Allouche, M., Campo, E., Delsol, G., et al. (2004) · Oncogene · doi:10.1038/sj.onc.1207813 · Cited by 129
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A. C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 128
Lee, J. E., Park, H. S., Lee, D., Yoo, G., Kim, T., Jeon, H., Yeo, M., Lee, C. S., Moon, J. Y., Jung, S. S., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.04.089 · Cited by 128
Murakami, A., Takahashi, F., Nurwidya, F., Kobayashi, I., Minakata, K., Hashimoto, M., Nara, T., Kato, M., Tajima, K., Shimada, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086459 · Cited by 125
YAP promotes erlotinib resistance in human non-small cell lung cancer cells
Hsu, P., You, B., Yang, Y., Zhang, W., Wang, Y., Xu, Z., Dai, Y., Liu, S., Yang, C., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10458 · Cited by 125
The frequency and clinical impact of HER2 alterations in lung adenocarcinoma
Kim, E., Kim, K., Lee, C. Y., & Shim, H. S. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171280 · Cited by 124
Cerebrospinal Fluid Concentrations of Gefitinib in Patients With Lung Adenocarcinoma
Zhao, J., Chen, M., Zhong, W., Zhang, L., Li, L., Xiao, Y., Nie, L., Hu, P., & Wang, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.004 · Cited by 123
Kim, H. R., Kim, W. S., Choi, Y. J., Choi, C., Rho, J. K., & Lee, J. C. (2013) · Molecular Oncology · doi:10.1016/j.molonc.2013.08.001 · Cited by 122
Yamada, T., Takeuchi, S., Nakade, J., Kita, K., Nakagawa, T., Nanjo, S., Nakamura, T., Matsumoto, K., Soda, M., Mano, H., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2972 · Cited by 122
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
Amato, K. R., Wang, S., Tan, L., Hastings, A. K., Song, W., Lovly, C. M., Meador, C. B., Ye, F., Wang, L., Balko, J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0717 · Cited by 121
Drilon, A. E. D. C., Camidge, D. R., Ou, S. I., Clark, J. W., Socinski, M. A., Weiss, J. M., Riely, G. J., Winter, M., Wang, S. C., Monti, K. L., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.108 · Cited by 119
A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer
Lira, M. E., Choi, Y., Lim, S. M., Deng, S., Huang, D., Ozeck, M., Han, J., Jeong, J. Y., Shim, H. S., Cho, B. C., et al. (2014) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2013.11.007 · Cited by 116
Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb‐B2
Clamon, G. H., Herndon, J. E., Kern, J. A., Govindan, R., Garst, J. L., Watson, D. M., & Green, M. (2005) · Cancer · doi:10.1002/cncr.20950 · Cited by 115
Lara, P. N., Laptalo, L., Longmate, J., Lau, D. H., Gandour‐Edwards, R. F., Gumerlock, P. H., Doroshow, J. H., & Gandara, D. R. (2004) · Clinical Lung Cancer · doi:10.3816/clc.2004.n.004 · Cited by 112
Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer
Lin, L., Asthana, S., Chan, E., Bandyopadhyay, S., Martins, M. M., Olivas, V. R., Yan, J. J., Pham, L. Q., Wang, M. M., Bollag, G. E., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320956111 · Cited by 106
Self-citationChung, F., Lee, K., Wang, C., Heh, C., Chan, Y., Chen, H., Kuo, C.-H. S., Feng, P., Lin, T., Wang, C., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.27403 · Cited by 104
Clinical Activity of Alectinib in Advanced RET -Rearranged Non–Small Cell Lung Cancer
Lin, J. J., Kennedy, E., Sequist, L. V. D., Brastianos, P. K., Goodwin, K. E., Stevens, S. E., Wanat, A. C., Stober, L. L., Digumarthy, S. R., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.126 · Cited by 104
ERBB2 -Mutated Metastatic Non–Small Cell Lung Cancer: Response and Resistance to Targeted Therapies
Chuang, J. C., Stehr, H., Liang, Y., Das, M. S., Huang, J. Q., Diehn, M., Wakelee, H. A., & Neal, J. W. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.01.023 · Cited by 102
Yamaguchi, N., Lucena-Araujo, A. R., Nakayama, S., de Figueiredo‐Pontes, L. L., Gonzalez, D. A., Yasuda, H., Kobayashi, S. S., & Costa, D. B. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.09.019 · Cited by 101
Tanimoto, A., Takeuchi, S., Arai, S., Fukuda, K., Yamada, T., Roca, X., Ong, S. T., & Yano, S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2271 · Cited by 101
Yoshida, T., Song, L., Bai, Y., Kinose, F., Li, J., Ohaegbulam, K. C., Muñoz-Antonia, T., Qu, X., Eschrich, S. A., Uramoto, H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0147344 · Cited by 99
Klughammer, B., Brugger, W., Cappuzzo, F., Ciuleanu, T., Mok, T., Reck, M., Tan, E. H., Delmar, P., Klingelschmitt, G., Yin, A.-Y., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.107 · Cited by 98
Phase II Trial of Gefitinib and Everolimus in Advanced Non-small Cell Lung Cancer
Price, K. A. R., Azzoli, C. G., Krug, L. M., Pietanza, M. C., Rizvi, N. A., Pao, W. J., Kris, M. G., Riely, G. J., Heelan, R. T., Arcila, M. E., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181ec1531 · Cited by 97
Li, A., Yang, J., Zhang, X., Zhang, Z., Su, J., Gou, L.-Y., Bai, Y., Zhou, Q. H., Yang, Z., Han‐Zhang, H., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3273 · Cited by 97
Identification of CCDC6-RET Fusion in the Human Lung Adenocarcinoma Cell Line, LC-2/ad
Matsubara, D., Kanai, Y., Ishikawa, S., Ohara, S., Yoshimoto, T., Sakatani, T., Oguni, S., Tamura, T., Kataoka, H., Endo, S., et al. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182721ed1 · Cited by 96
Reguart, N., Rosell, R., Cardenal, F., Cardona, A. F., Isla, D., Palmero, R., Morán, T., Rolfo, C. D., Pallarès, M. C., Insa, A., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.02.011 · Cited by 95
Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000113 · Cited by 93
Wu, F., Li, J., Jang, C., Wang, J., & Xiong, J. (2014) · PubMed · Cited by 91
Wald, O., Izhar, U., Amir, G., Kirshberg, S., Shlomai, Z., Zamir, G. A., Peled, A., & Shapira, O. M. (2011) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2010.11.056 · Cited by 90
Cha, Y. J., Cho, B. C., Kim, H. R., Lee, H., & Shim, H. S. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.097 · Cited by 90
Mink, S. R., Vashistha, S., Zhang, W., Hodge, A., Agus, D. B., & Jain, A. (2010) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0460 · Cited by 89
Tao, Z., Blanc, J. M. L., Wang, C., Zhan, T., Zhuang, H., Wang, P., Yuan, Z., & Lü, B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0589 · Cited by 89
Clinical and Molecular Characteristics of NF1 -Mutant Lung Cancer
Redig, A. J., Capelletti, M., Dahlberg, S. E., Sholl, L. M., Mach, S. L., Fontes, C., Shi, Y., Chalasani, P., & Janne, P. A. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2377 · Cited by 84
An Activating KIT Mutation Induces Crizotinib Resistance in ROS1-Positive Lung Cancer
Dziadziuszko, R., Le, A. T., Wrona, A., Jassem, J., Camidge, D. R., Varella‐Garcia, M., Aisner, D. L., & Doebele, R. C. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.04.001 · Cited by 83
Nelson-Taylor, S. K., Le, A. T., Yoo, M., Schubert, L., Mishall, K. M., Doak, A. E., Varella‐Garcia, M., Tan, A. C., & Doebele, R. C. (2017) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0008 · Cited by 83
A genetic cell context-dependent role for ZEB1 in lung cancer
Zhang, T., Guo, L., Creighton, C. J., Lü, Q., Gibbons, D. L., Yi, E. S., Deng, B., Molina, J. R., Sun, Z., Yang, P., et al. (2016) · Nature Communications · doi:10.1038/ncomms12231 · Cited by 81
Activation of RAS family members confers resistance to ROS1 targeting drugs
Cargnelutti, M., Corso, S., Pergolizzi, M., Mévellec, L., Aisner, D. L., Dziadziuszko, R., Varella‐Garcia, M., Comoglio, P. M., Doebele, R. C., Vialard, J. E., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.3311 · Cited by 80
Kim, J., Welsh, E. A., Fang, B., Bai, Y., Kinose, F., Eschrich, S. A., Koomen, J. M., & Haura, E. B. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0506 · Cited by 78
Okimoto, R. A., Lin, L., Olivas, V. R., Chan, E., Markegard, E., Rymar, A., Neel, D. S., Chen, X., Hemmati, G., Bollag, G. E., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610456113 · Cited by 78
Self-citationEGFR Mediates Responses to Small-Molecule Drugs Targeting Oncogenic Fusion Kinases
Vaishnavi, A., Schubert, L., Rix, U., Marek, L. A., Le, A. T., Keysar, S. B., Glogowska, M. J., Smith, M. A., Kako, S. L., Sumi, N. J., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0109 · Cited by 76
Greve, G., Schiffmann, I., Pfeifer, D., Pantić, M., Schüler, J. B., & Lübbert, M. (2015) · BMC Cancer · doi:10.1186/s12885-015-1967-5 · Cited by 75
Preclinical Modeling of KIF5B–RET Fusion Lung Adenocarcinoma
Huang, Q., Schneeberger, V. E., Luetteke, N., Jin, C., Afzal, R., Budzevich, M. M., Makanji, R. J., Martinez, G. V., Shen, T., Zhao, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0258 · Cited by 75
Minakata, K., Takahashi, F., Nara, T., Hashimoto, M., Tajima, K., Murakami, A., Nurwidya, F., Yae, S., Koizumi, F., Moriyama, H., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02408.x · Cited by 73
Tabara, K., Kanda, R., Sonoda, K., Kubo, T., Murakami, Y., Kawahara, A., Azuma, K., Abe, H., Kage, M., Yoshinaga, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041017 · Cited by 72
Dong, X., Fernández‐Salas, E., Li, E., & Wang, S. (2016) · Neoplasia · doi:10.1016/j.neo.2016.02.001 · Cited by 72
Choe, C., Shin, Y.-S., Choi, S., Lee, J., Kim, S. Y., Cho, Y. B., Kim, J., & Kim, C. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s89659 · Cited by 71
An overview of the design and conduct of the BATTLE trials.
Liu, S., & Lee, J. J. (2015) · PubMed · doi:10.3978/j.issn.2304-3865.2015.06.07 · Cited by 69
JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors
Gao, S. P., Chang, Q., Mao, N., Daly, L., VOGEL, R. M., Chan, T., Liu, S. H., Bournazou, E., Schori, E., Zhang, H., et al. (2016) · Science Signaling · doi:10.1126/scisignal.aac8460 · Cited by 69
Tani, T., Yasuda, H., Hamamoto, J., Kuroda, A., Arai, D., Ishioka, K., Ohgino, K., Miyawaki, M., Kawada, I., Naoki, K., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0084 · Cited by 68
Ramalingam, S. S., Yang, J. C.-H., Lee, C. K., Kurata, T., Kim, D.-W., John, T., Nogami, N., Ohe, Y., & Janne, P. A. (2016) · Journal of Thoracic Oncology · doi:10.1016/s1556-0864(16)30324-0 · Cited by 68
Karachaliou, N., Codony‐Servat, J., Teixidó, C., Pilotto, S., Drozdowskyj, A., Codony, C., Giménez-Capitán, A. A., Molina‐Vila, M. Á., Bertrán-Alamillo, J., Gervais, R., et al. (2015) · Scientific Reports · doi:10.1038/srep17499 · Cited by 65
Han, J., Lee, S. H., Lee, G. K., Yun, T., Lee, Y. J., Hwang, K. H., Kim, J. Y., & Kim, H. T. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2664-9 · Cited by 64
Trametinib with or without Vemurafenib in BRAF Mutated Non-Small Cell Lung Cancer
Joshi, M., Rice, S. J., Liu, X., Miller, B., & Belani, C. P. (2015) · PLoS ONE · doi:10.1371/journal.pone.0118210 · Cited by 62
Kogita, A., Togashi, Y., Hayashi, H., Sogabe, S., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., Tomida, S., Takeyama, Y., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2574 · Cited by 62
Yoshida, T., Okamoto, I., Okamoto, W., Hatashita, E., Yamada, Y., Kuwata, K., Nishio, K., Fukuoka, M., Janne, P. A., & Nakagawa, K. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01368.x · Cited by 62
Qiu, B., Liang, Y., Li, Q.-W., Liu, G.-H., Wang, F., Chen, Z., Liu, M., Zhao, M. D., & Liu, H. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.04.002 · Cited by 62
Janne, P. A., Shaw, A. T., Camidge, D. R., Giaccone, G., Shreeve, S. M., Tang, Y., Goldberg, Z., Martini, J., Xu, H., James, L. P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.022 · Cited by 58
Yu, H. A., Perez, L., Chang, Q., Gao, S. P., Kris, M. G., Riely, G. J., & Bromberg, J. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.140 · Cited by 58
Ou, S. I., Govindan, R., Eaton, K. D., Otterson, G. A., Gutierrez, M. E., Mita, A. C., Argiris, A. E., Brega, N. M., Usari, T., Tan, W., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.09.131 · Cited by 53
Gandhi, L., Besse, B., Mazières, J., Waqar, S. N., Cortot, A. B., Barlési, F., Quoix, É., Otterson, G. A., Ettinger, D. S., Horn, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.398 · Cited by 53
Shou, J., You, L., Yao, J., Xie, J., Jing, J., Zhao, J., Jiang, L., Sui, X., Pan, H., & Han, W. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.06.002 · Cited by 52
Zhang, L., Jiang, T., Li, X., Wang, Y., Zhao, C., Zhao, S., Xi, L., Zhang, S., Liu, X., Jia, Y., et al. (2017) · Cancer · doi:10.1002/cncr.30677 · Cited by 52
Janne, P. A., Cohen, R. B., Laird, A., Macé, S., Engelman, J. A., Ruiz-Soto, R., Rockich, K. T., Xu, J., Shapiro, G. I., Martínez, P., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000088 · Cited by 49
Liu, M., Xu, S., Wang, Y., Li, Y., Li, Y., Zhang, H., Liu, H., & Chen, J. (2016) · Oncotarget · doi:10.18632/oncotarget.13069 · Cited by 48
Jiang, J., Gu, Y., Liu, J., Wu, R., Fu, L., Zhao, J., & Guan, Y. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.10.015 · Cited by 47
Oxnard, G. R., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Yu, H. A., Saka, H., Horn, L., Goto, K., Ohe, Y., Cantarini, M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.2509 · Cited by 46
A Phase I/II Study Combining Erlotinib and Dasatinib for Non-Small Cell Lung Cancer
Gold, K. A., Lee, J. J., Harun, N., Tang, X., Price, J., Kawedia, J. D., Tran, H. T., Erasmus, J. J., Blumenschein, G. R., William, W. N., et al. (2014) · The Oncologist · doi:10.1634/theoncologist.2014-0228 · Cited by 46
Kobayashi, Y., Sakao, Y., Ito, S., Jangchul, P., Kuroda, H., Sakakura, N., Usami, N., Mitsudomi, T., & Yatabe, Y. (2013) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318293d96f · Cited by 45
Wu, Y.-L. L. C., Yang, J. C., Kim, D., Su, W., Ahn, M., Lee, K. H., Vansteenkiste, J., Zhang, L., Felip, E., Peng, B., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8017 · Cited by 44
EGF Induced RET Inhibitor Resistance inCCDC6-RETLung Cancer Cells
Chang, H. K., Sung, J. H., Moon, S. U., Kim, H.-S., Kim, J. W., & Lee, J. S. (2016) · Yonsei Medical Journal · doi:10.3349/ymj.2017.58.1.9 · Cited by 41
Gu, F., Zhang, Y., Liu, Y., Hong, X.-H., Liang, J., Tong, F., Yang, J., & Liu, L. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0296-8 · Cited by 40
Chiba, M., Togashi, Y., Bannno, E., Kobayashi, Y., Nakamura, Y., Hayashi, H., Terashima, M., Velasco, M. A. D., Sakai, K., Fujita, Y., et al. (2017) · BMC Cancer · doi:10.1186/s12885-017-3263-z · Cited by 40
Widemann, B. C., Marcus, L. J., Fisher, M. J., Weiss, B., Kim, A., Dombi, E., Baldwin, A. M., Whitcomb, P. O., Martin, S. C., Gillespie, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.10018 · Cited by 39
Wakelee, H. A., Gettinger, S. N., Engelman, J. A., Janne, P. A., West, H., Subramaniam, D. S., Leach, J., Wax, M., Yaron, Y., Miles, D., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3283-z · Cited by 39
Gower, A., Hsu, W., Hsu, S.-T., Wang, Y., & Giaccone, G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.11.007 · Cited by 38
Suda, K., Murakami, I., Sakai, K., Tomizawa, K., Mizuuchi, H., Sato, K., Nishio, K., & Mitsudomi, T. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.016 · Cited by 37
Jönsson, V. D., Blakely, C. M., Lin, L., Asthana, S., Matni, N., Olivas, V. R., Pazarentzos, E., Gubens, M. A., Bastian, B. C., Taylor, B. S., et al. (2017) · Scientific Reports · doi:10.1038/srep44206 · Cited by 36
Self-citationN-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells.
Yamauchi, M., Yoshino, I., Yamaguchi, R., Shimamura, T., Nagasaki, M., Imoto, S., Niida, A., Koizumi, F., Kohno, T., Yokota, J., et al. (2011) · Europe PMC (PubMed Central) · Cited by 35
An, J., Enomoto, A., Weng, L., Kato, T., Iwakoshi, A., Ushida, K., Maeda, K., Takagishi, M., Ishii, G., Ming, S., et al. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1328-6 · Cited by 34
Morán, T., Felip, E., Keedy, V. L., Borghaei, H., Shepherd, F. A., Insa, A., Brown, H. M., Fitzgerald, T. P., Sathyanarayanan, S., Reilly, J. F., et al. (2014) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-3-26 · Cited by 33
Taniguchi, H., Takeuchi, S., Fukuda, K., Nakagawa, T., Arai, S., Nanjo, S., Yamada, T., Yamaguchi, H., Mukae, H., & Yano, S. (2016) · Cancer Science · doi:10.1111/cas.13111 · Cited by 33
Mok, T. S. K., Cheng, Y., Zhou, X., Lee, K. H., Nakagawa, K., Niho, S., Tsuji, F., Rosell, R., Jaime, J. C., Migliorino, M. R., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.35.18_suppl.lba9007 · Cited by 33
Subbiah, V., Hong, D. S., & Meric‐Bernstam, F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1522052113 · Cited by 32
Kawabata, S., Mercado-Matos, J., Hollander, M. C., Donahue, D., Wilson, W., Regales, L., Butaney, M., Pao, W. J., Wong, K., Janne, P. A., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.05.039 · Cited by 30
Tan, D. S.-W., Lim, K. H., Tai, W. M. D., Ahmad, A., Pan, S., Ng, Q. S., Ang, M., Gogna, A., Ng, Y. L., Tan, B. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8107 · Cited by 30
Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.8026 · Cited by 27
TGF-β1 induces erlotinib resistance in non-small cell lung cancer by down-regulating PTEN
Shen, H., Guan, D., Shen, J., Wang, M., Chen, X., Xu, T., Liu, L., & Shu, Y. (2015) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2015.10.018 · Cited by 26
FRMD4A / RET : A Novel RET Oncogenic Fusion Variant in Non–Small Cell Lung Carcinoma
Velcheti, V., Thawani, R., Khunger, M., Mukhopadhyay, S., Chute, D. J., Schrock, A. B., & Ali, S. M. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.274 · Cited by 25
Jackman, D. M., Mach, S. L., Heng, J. C., Rabin, M. S., Barbie, D. A., Gandhi, L., Marcoux, J. P., & Costa, D. B. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.8116 · Cited by 25
Deng, Q., Su, B., ZHAO, Y. M., Tang, L., ZHANG, J., & ZHOU, C.-C. (2015) · Oncology Letters · doi:10.3892/ol.2015.3945 · Cited by 23
Bae, S. Y., Park, H. J., Hong, J., Lee, H., & Lee, S. K. (2016) · Scientific Reports · doi:10.1038/srep32258 · Cited by 23
Rho, J. K., Lee, I. Y., Choi, Y. J., Choi, C., Hur, J.-Y., Koh, J. S., Lee, J., Suh, B., Song, H., Salgaonkar, P., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2432 · Cited by 17
Self-citationDudnik, E., Siegal, T., Zach, L., Allen, A. M., Flex, D., Yust‐Katz, S., Limon, D., Hirsch, F. R., & Peled, N. (2015) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2015.05.068 · Cited by 16
AZD 0530 sensitizes drug‐resistant ALK ‐positive lung cancer cells by inhibiting SRC signaling
Zhao, Y., Yang, Y., Xu, Y., Lu, S., & Jian, H. (2016) · FEBS Open Bio · doi:10.1002/2211-5463.12162 · Cited by 15
Tamiya, A., Tamiya, M., Nishihara, T., Shiroyama, T., Nakao, K., Tsuji, T., Takeuchi, N., Isa, S., Omachi, N., Okamoto, N., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.270 · Cited by 7
Cited by
Thai, A. A., Solomon, B. J., Sequist, L. V., Gainor, J. F., & Heist, R. S. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00312-3 · Cited by 2,576
Targeting apoptosis in cancer therapy
Carneiro, B. A., & El-Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,542
Comprehensive review of targeted therapy for colorectal cancer
Xie, Y.-H., Chen, Y.-X., & Fang, J.-Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0116-z · Cited by 1,687
Toward personalized treatment approaches for non-small-cell lung cancer
Wang, M., Herbst, R. S., & Boshoff, C. (2021) · Nature Medicine · doi:10.1038/s41591-021-01450-2 · Cited by 1,093
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Metadata
- Authors
- Rotow, J., & Bivona, T. G.
- Venue
- Nature Reviews Cancer
- Published
- 2017-10-25
- Volume
- 17
- Issue
- 11
- Pages
- 637-658
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2765831845
- Cited by
- 972
- References
- 304
- FWCI
- 17.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.